JP2011103891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011103891A5 JP2011103891A5 JP2011010411A JP2011010411A JP2011103891A5 JP 2011103891 A5 JP2011103891 A5 JP 2011103891A5 JP 2011010411 A JP2011010411 A JP 2011010411A JP 2011010411 A JP2011010411 A JP 2011010411A JP 2011103891 A5 JP2011103891 A5 JP 2011103891A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- acid residues
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004881 tumor cell Anatomy 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 10
- 229920001184 polypeptide Polymers 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 101150092419 STRA6 gene Proteins 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 229940127089 cytotoxic agent Drugs 0.000 claims 7
- 150000004492 retinoid derivatives Chemical class 0.000 claims 7
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000002254 cytotoxic agent Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 102000052547 Wnt-1 Human genes 0.000 claims 3
- 108700020987 Wnt-1 Proteins 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 208000023965 endometrium neoplasm Diseases 0.000 claims 3
- 230000009395 genetic defect Effects 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000037841 lung tumor Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 208000028591 pheochromocytoma Diseases 0.000 claims 3
- 102000015735 Beta-catenin Human genes 0.000 claims 2
- 108060000903 Beta-catenin Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 229930002330 retinoic acid Natural products 0.000 claims 2
- 229960001727 tretinoin Drugs 0.000 claims 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17584900P | 2000-01-13 | 2000-01-13 | |
| US60/175,849 | 2000-01-13 | ||
| US19708900P | 2000-04-14 | 2000-04-14 | |
| US60/197,089 | 2000-04-14 | ||
| US22891400P | 2000-08-29 | 2000-08-29 | |
| US60/228,914 | 2000-08-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Division JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011103891A JP2011103891A (ja) | 2011-06-02 |
| JP2011103891A5 true JP2011103891A5 (enExample) | 2012-11-29 |
| JP5701624B2 JP5701624B2 (ja) | 2015-04-15 |
Family
ID=27390600
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Pending JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
| JP2011010411A Expired - Fee Related JP5701624B2 (ja) | 2000-01-13 | 2011-01-21 | 新規なｓｔｒａ６ポリペプチド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001551209A Pending JP2003519491A (ja) | 2000-01-13 | 2001-01-11 | 新規なｓｔｒａ６ポリペプチド |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US7173115B2 (enExample) |
| EP (1) | EP1246917B1 (enExample) |
| JP (2) | JP2003519491A (enExample) |
| KR (2) | KR20080006002A (enExample) |
| CN (2) | CN101643733A (enExample) |
| AT (1) | ATE424457T1 (enExample) |
| AU (2) | AU785055B2 (enExample) |
| CA (1) | CA2397207C (enExample) |
| DE (1) | DE60137829D1 (enExample) |
| DK (1) | DK1246917T3 (enExample) |
| ES (1) | ES2323220T3 (enExample) |
| IL (2) | IL150676A0 (enExample) |
| NZ (1) | NZ520095A (enExample) |
| PT (1) | PT1246917E (enExample) |
| WO (1) | WO2001051635A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60137829D1 (de) * | 2000-01-13 | 2009-04-16 | Genentech Inc | Menschliche stra6 polypeptide |
| WO2002077027A1 (en) * | 2000-03-23 | 2002-10-03 | Curagen Corporation | Human stra6-like protein and nucleic acids encoding the same |
| CN1339489A (zh) * | 2000-08-23 | 2002-03-13 | 上海博德基因开发有限公司 | 一种新的多肽——人视黄酸效应蛋白53.57和编码这种多肽的多核苷酸 |
| NZ524230A (en) * | 2000-08-29 | 2006-05-26 | Genentech Inc | Identification of tumor antigens the expression of which is selectively enhanced by retinoid treatment |
| US7682607B2 (en) * | 2001-05-01 | 2010-03-23 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| DK2258872T3 (da) * | 2002-03-13 | 2013-11-18 | Genomic Health Inc | Genekspressionsprofilering i biopsier af tumorvæv |
| US7666627B2 (en) * | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| CN1741821B (zh) * | 2002-10-29 | 2011-08-10 | 恩根尼公司 | 用于癌症治疗的组合物 |
| JP2007525946A (ja) * | 2003-04-30 | 2007-09-13 | セントカー・インコーポレーテツド | Ｃｎｇｈ００１０特異的ポリヌクレオチド、ポリペプチド、抗体、組成物、方法および使用 |
| US20060074480A1 (en) * | 2004-09-01 | 2006-04-06 | Pst, Llc | Stent and method for manufacturing the stent |
| US20090048196A1 (en) * | 2007-01-18 | 2009-02-19 | The Regents Of The University Of California | Membrane receptor for retinol binding protein mediates cellular uptake of vitamin A, methods of use and compositions |
| US20110159017A1 (en) * | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
| US20120183477A1 (en) * | 2009-06-26 | 2012-07-19 | Five Prime Therapeutics, Inc. | Therapeutic Antibody Target Validation and Screening In Vivo |
| ES3027507T3 (en) * | 2010-01-11 | 2025-06-16 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| DK2598659T3 (en) * | 2010-07-27 | 2015-05-26 | Genomic Health Inc | PROCEDURE FOR USING GENEPRESSION FOR DETERMINING PROSTATE CANCER FORECAST |
| CA2863040C (en) | 2012-01-31 | 2022-04-19 | Genomic Health, Inc. | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| HK1211037A1 (en) | 2012-02-11 | 2016-05-13 | 霍夫曼-拉罗奇有限公司 | R-spondin translocations and methods using the same |
| CA2903878C (en) | 2013-05-30 | 2020-10-27 | Genomic Health, Inc. | Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer |
| EP3636661A1 (en) * | 2018-10-12 | 2020-04-15 | Bioc3 | Phosphate translocator |
| CN116287211B (zh) * | 2023-03-24 | 2025-10-10 | 中国医学科学院北京协和医院 | STRA6和miR-1249-5p在制备诊断子宫腺肌症的产品中的应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4444545A (en) * | 1982-04-08 | 1984-04-24 | Sanders David F | Pump control system |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4676417A (en) * | 1986-04-14 | 1987-06-30 | Richard Hirschkoff | Ski carrier |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US4997852A (en) | 1987-08-26 | 1991-03-05 | Ohio State University Research Foundation | Method and composition for achieving cancer chemopreventive and chemotherapeutic activity |
| IL87737A (en) | 1987-09-11 | 1993-08-18 | Genentech Inc | Method for culturing polypeptide factor dependent vertebrate recombinant cells |
| KR0154872B1 (ko) | 1987-12-21 | 1998-10-15 | 로버트 에이. 아미테이지 | 발아하는 식물종자의 아크로박테리움 매개된 형질전환 |
| SE8802525L (sv) | 1988-07-06 | 1990-01-07 | Fmg Filipstad Ab | Stol |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| ATE144281T1 (de) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der gattung-schwanniomyces |
| EP0471796A4 (en) | 1989-05-10 | 1993-05-05 | Sloan Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5731167A (en) | 1992-01-17 | 1998-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy |
| US5756448A (en) | 1992-02-26 | 1998-05-26 | The General Hospital Corporation | Constitute activator of retinoid (CAR) receptor polypeptides |
| DE69330750T2 (de) | 1992-03-04 | 2002-07-04 | The Regents Of The University Of California, Oakland | Vergleichende genomhybridisierung |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| DK0674506T3 (da) | 1992-12-02 | 2001-01-08 | Alkermes Inc | Væksthormonholdige mikrosfærer med styret frigivelse |
| US5547947A (en) * | 1993-03-11 | 1996-08-20 | Hoffmann-La Roche Inc. | Methods of treatment |
| ATE186219T1 (de) | 1993-03-24 | 1999-11-15 | Berlex Biosciences | Kombination von antihormonale und bindende moleküle zur krebsbehandlung |
| US5681860A (en) | 1993-09-21 | 1997-10-28 | The Trustees Of Columbia University In The City Of New York | Method of increasing expression of HLA, cell surface and TAA antigens of cells using 3-(N-acetylamino)-5-(N-decyl-N-methylamino)-benzyl alcohol |
| DE69519382T3 (de) | 1994-09-09 | 2008-09-18 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter freigabe eines metallsalz eines peptids |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6316007B1 (en) | 1995-04-04 | 2001-11-13 | Wound Healing Of Oklahoma | Combined physical and immunotherapy for cancer |
| WO1996040072A2 (en) | 1995-06-07 | 1996-12-19 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US5871697A (en) * | 1995-10-24 | 1999-02-16 | Curagen Corporation | Method and apparatus for identifying, classifying, or quantifying DNA sequences in a sample without sequencing |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6525174B1 (en) * | 1997-06-06 | 2003-02-25 | Human Genome Sciences, Inc. | Precerebellin-like protein |
| CA2291260A1 (en) * | 1997-06-06 | 1998-12-10 | Human Genome Sciences, Inc. | 207 human secreted proteins |
| EP1206536A2 (en) | 1999-08-17 | 2002-05-22 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| DE60137829D1 (de) * | 2000-01-13 | 2009-04-16 | Genentech Inc | Menschliche stra6 polypeptide |
| WO2002077027A1 (en) | 2000-03-23 | 2002-10-03 | Curagen Corporation | Human stra6-like protein and nucleic acids encoding the same |
| US20030100711A1 (en) | 2000-06-05 | 2003-05-29 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030187201A1 (en) | 2000-09-15 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7157558B2 (en) | 2001-06-01 | 2007-01-02 | Genentech, Inc. | Polypeptide encoded by a polynucleotide overexpresses in tumors |
-
2001
- 2001-01-11 DE DE60137829T patent/DE60137829D1/de not_active Expired - Lifetime
- 2001-01-11 AT AT01904821T patent/ATE424457T1/de active
- 2001-01-11 PT PT01904821T patent/PT1246917E/pt unknown
- 2001-01-11 EP EP01904821A patent/EP1246917B1/en not_active Expired - Lifetime
- 2001-01-11 CA CA2397207A patent/CA2397207C/en not_active Expired - Fee Related
- 2001-01-11 NZ NZ520095A patent/NZ520095A/en not_active IP Right Cessation
- 2001-01-11 US US09/759,056 patent/US7173115B2/en not_active Expired - Fee Related
- 2001-01-11 IL IL15067601A patent/IL150676A0/xx unknown
- 2001-01-11 DK DK01904821T patent/DK1246917T3/da active
- 2001-01-11 WO PCT/US2001/000847 patent/WO2001051635A2/en not_active Ceased
- 2001-01-11 JP JP2001551209A patent/JP2003519491A/ja active Pending
- 2001-01-11 CN CN200910147020A patent/CN101643733A/zh active Pending
- 2001-01-11 AU AU32768/01A patent/AU785055B2/en not_active Ceased
- 2001-01-11 CN CN018064965A patent/CN1425066B/zh not_active Expired - Fee Related
- 2001-01-11 ES ES01904821T patent/ES2323220T3/es not_active Expired - Lifetime
- 2001-01-11 KR KR1020077028133A patent/KR20080006002A/ko not_active Ceased
- 2001-07-10 US US09/901,812 patent/US20020173461A1/en not_active Abandoned
-
2002
- 2002-07-10 IL IL150676A patent/IL150676A/en not_active IP Right Cessation
- 2002-07-12 KR KR1020027009049A patent/KR100929057B1/ko not_active Expired - Fee Related
-
2006
- 2006-05-22 US US11/438,488 patent/US7741439B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/458,181 patent/US7939650B2/en not_active Expired - Fee Related
- 2006-07-18 US US11/458,237 patent/US20070025998A1/en not_active Abandoned
- 2006-11-24 AU AU2006241374A patent/AU2006241374B2/en not_active Ceased
-
2007
- 2007-10-31 US US11/932,861 patent/US7855278B2/en not_active Expired - Fee Related
-
2010
- 2010-11-11 US US12/944,519 patent/US20110171238A1/en not_active Abandoned
-
2011
- 2011-01-21 JP JP2011010411A patent/JP5701624B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2899954T3 (es) | Métodos para tratar el cáncer de piel mediante la administración de un inhibidor de PD-1 | |
| Trivedi et al. | Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells | |
| JP2026053616A (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む治療法 | |
| ES2931337T3 (es) | Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red | |
| US20210069147A1 (en) | Pharmaceutical combination and uses thereof | |
| MX348577B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| HK1259190A1 (zh) | 嵌合抗原受体相关的方法和组合物 | |
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| MX348578B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| JP2012102122A5 (enExample) | ||
| RU2012137503A (ru) | Лекарственный препарат для лечения и/или профилактики рака | |
| JP7304595B2 (ja) | ｕＰＡＲＡＰを標的にする抗体薬物複合体 | |
| Tagliamonte et al. | Potentiating cancer vaccine efficacy in liver cancer | |
| Yu et al. | Synergistic antitumor effects of 9.2. 27-PE38KDEL and ABT-737 in primary and metastatic brain tumors | |
| Bossi et al. | Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| JP2023011902A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| Wang et al. | Rab GTPase 21 mediates caerulin-induced TRAF3-MKK3-p38 activation and acute pancreatitis response | |
| WO2021182571A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| WO2018209017A1 (en) | Cancer treatment with a cxcl12 signaling inhibitor and an immune checkpoint inhibitor | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| CN102935228B (zh) | 用于肿瘤治疗的试剂、其用途及方法 | |
| WO2021182572A1 (ja) | 癌の治療及び／又は予防のための医薬品 |